Arcus Biosciences, Inc. Contracts & Agreements

Loan & Security Agreement, between the Registrant, Hercules Capital, Inc. and the lenders listed therein, dated August 27, 2024 (Filed With SEC on November 6, 2024)

Amendment No. 4 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated May 10, 2024 (Filed With SEC on August 8, 2024)

Non-Employee Director Compensation Program (Filed With SEC on June 6, 2024)

Arcus Biosciences, Inc. Severance Benefits Plan (Filed With SEC on February 21, 2024)

Amendment No. 3 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated January 2 (Filed With SEC on February 21, 2024)

Memorandum, dated July 27, 2023, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., LTD (Filed With SEC on November 7, 2023)

Amendment No. 2 to the Option, License and Collaboration Agreement, dated May 15, 2023, between Arcus Biosciences, Inc. and Gilead Sciences, Inc (Filed With SEC on August 7, 2023)

Non-Employee Director Compensation Program (Filed With SEC on June 16, 2023)

Letter Agreement, dated July 25, 2022, between the Registrant and Dimitry S.A. Nuyten, MD., Ph.D (Filed With SEC on November 2, 2022)

Amendment No. 1 to Investor Rights Agreement, dated October 11, 2022 (Filed With SEC on October 11, 2022)

Letter Agreement with Gilead Sciences, Inc. dated July 1, 2022 (Filed With SEC on August 3, 2022)

Non-Employee Director Compensation Program (Filed With SEC on June 16, 2022)

Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan (Filed With SEC on February 23, 2022)

Amendment No. 1 dated November 17, 2021 to the Option, License and Collaboration Agreement dated May 27, 2020 between Arcus Biosciences, Inc. and Gilead Sciences, Inc (Filed With SEC on February 23, 2022)

Third Amendment dated May 10, 2021 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics Ireland Limited (Filed With SEC on August 5, 2021)

Separation and Consulting Agreement by and between the Company and William Grossman dated July 16, 2021 (Filed With SEC on August 5, 2021)

Non-Employee Director Compensation Program (Filed With SEC on June 7, 2021)

Fifth Amendment Dated April 1, 2021 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership (Filed With SEC on May 5, 2021)

Description of Common Stock (Filed With SEC on February 25, 2021)

Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan (Filed With SEC on February 25, 2021)

Dated November 10, 2020 Arcus Biosciences, Inc. WuXi Biologics (Cayman) Inc. and WuXi Biologics Ireland Limited (Filed With SEC on February 25, 2021)

Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Stock Option Grant (Filed With SEC on February 25, 2021)

Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Restricted Stock Unit Award (Filed With SEC on February 25, 2021)

Offer letter by and between Arcus Biosciences, Inc. and Robert C. Goeltz II dated June 30, 2020 (Filed With SEC on November 5, 2020)

Offer letter by and between Arcus Biosciences, Inc. and Jennifer Jarrett dated September 10, 2020 (Filed With SEC on November 5, 2020)

Fourth Amendment dated October 16, 2020 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership (Filed With SEC on November 5, 2020)

Non-Employee Director Compensation Program (Filed With SEC on June 5, 2020)

Underwriting Agreement, dated as of May 28, 2020, by and among Arcus Biosciences, Inc., Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C (Filed With SEC on May 29, 2020)

Description of Common Stock (Filed With SEC on March 5, 2020)

Compensation Program for Non-Employee Directors (Filed With SEC on March 5, 2020)

Amendment to Separation and Consulting Agreement by and between the Company and Jennifer Jarrett dated January 3, 2019 (Filed With SEC on March 5, 2020)

Arcus Biosciences, Inc. 2020 Inducement Plan (Filed With SEC on March 5, 2020)

Arcus Biosciences, Inc. Stock Option Grant Notice (2020 Inducement Plan) (Filed With SEC on March 5, 2020)

Arcus Biosciences, Inc. Restricted Stock Unit Grant Notice (2020 Inducement Plan) (Filed With SEC on March 5, 2020)

Amendment No. 2 dated March 2, 2020 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc (Filed With SEC on March 5, 2020)

Offer Letter, dated May 20, 2019, between the Company and Jason Barker (Filed With SEC on November 5, 2019)

Separation Agreement, dated August 29, 2019, between the Company and Rekha Hemrajani (Filed With SEC on November 5, 2019)

Offer Letter, dated March 16, 2019, between the Company and William Grossman (Filed With SEC on August 6, 2019)

Amendment No. 1 dated June 27, 2019 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc (Filed With SEC on August 6, 2019)

Offer Letter, dated February 22, 2019, between the Company and Rekha Hemrajani (Filed With SEC on May 2, 2019)

Separation and Consulting Agreement by and between the Company and Jennifer Jarrett dated January 3, 2019 (Filed With SEC on March 5, 2019)

Separation and Consulting Agreement by and between the Company and Steven Chan dated March 1, 2019 (Filed With SEC on March 5, 2019)

Amendment No. 1 to Option and License Agreement, dated September 19, 2017, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co, Ltd (Filed With SEC on November 8, 2018)

Form of Severance and Change in Control Agreement (for use from September 24, 2018) (Filed With SEC on November 8, 2018)

Form of Underwriting Agreement (Filed With SEC on March 5, 2018)

Arcus Biosciences, Inc. 2015 Stock Plan and forms of agreements thereunder (Filed With SEC on March 5, 2018)

Arcus Biosciences, Inc. 2018 Equity Incentive Plan, including form agreements, to be in effect upon completion of the offering (Filed With SEC on March 5, 2018)

Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, to be in effect upon the completion of the offering (Filed With SEC on March 5, 2018)

Amended and Restated Investors Rights Agreement, dated November 3, 2017, between the Registrant and the parties thereto (Filed With SEC on February 16, 2018)

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on February 16, 2018)

Arcus Biosciences, Inc. 2015 Stock Plan and forms of agreements thereunder (Filed With SEC on February 16, 2018)

Amended and Restated Letter Agreement, dated February 14, 2018, between the Registrant and Terry Rosen, Ph.D (Filed With SEC on February 16, 2018)

Amended and Restated Letter Agreement, dated February 14, 2018, between the Registrant and Juan Carlos Jaen, Ph.D (Filed With SEC on February 16, 2018)

Amended and Restated Letter Agreement, dated February 14, 2018, between the Registrant and Jennifer Jarrett (Filed With SEC on February 16, 2018)

Lease, dated September 30, 2015, between the Registrant and Hayward Point Eden I Limited Partnership, as amended on July 22, 2016 and October 12, 2017 (Filed With SEC on February 16, 2018)

Compensation Program for Non-Employee Directors (Filed With SEC on February 16, 2018)

License Agreement, dated December 8, 2016, between the Registrant and Abmuno Therapeutics LLC (Filed With SEC on February 16, 2018)

License Agreement, dated August 16, 2017, between the Registrant and WuXi Biologics (Cayman) Inc (Filed With SEC on February 16, 2018)

Option and License Agreement, dated September 19, 2017, between the Registrant and Taiho Pharmaceutical Co., Ltd (Filed With SEC on February 16, 2018)

Arcus Biosciences, Inc. Management Cash Incentive Plan (Filed With SEC on February 16, 2018)

Form of Severance and Change in Control Agreement (Filed With SEC on February 16, 2018)

Category

Industry

Companies

Contracts

Arcus Biosciences, Inc. Contracts & Agreements